2024 Platinum resistant recurrent ovarian cancer

Platinum resistant recurrent ovarian cancer

Author: vnmx

August undefined, 2024

WebbPurpose: To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum-resistant ovarian cancer in a real-world setting. Patients and methods: We … Webb10 apr. 2024 · Treatment with botensilimab plus balstilimab produced responses in patients with refractory or resistant ovarian cancer, according to results from a phase 1 study. Adding the T-cell primer to the PD-1 inhibitor led to objective responses in a third of patients with recurrent platinum-refractory/resistant ovarian cancer.

Bevacizumab combined with chemotherapy for platinum-resistant …

Webbför 2 dagar sedan · As part of the phase 3 GLORIOSA study (NCT05445778), a clinical trial is evaluating the safety and efficacy of the antibody drug conjugate (ADC) mirvetuximab … Webb4 mars 2024 · Platinum resistant means your cancer comes back within 6 months of finishing your last carboplatin treatment. Your doctor might describe your cancer as: … timmins 7 day weather forecast

Quality of life predicts overall survival in women with platinum ...

WebbBackground Therapy options for patients with recurrent, platinum-resistant ovarian cancer are limited. Cortisol contributes to chemotherapy resistance, one driver of poor outcomes, by suppressing apoptotic pathways used by cytotoxic agents. WebbThis study aimed to further explore the efficacy and safety of apatinib plus chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC). Methods: Totally, 105 patients with recurrent PROC receiving apatinib plus chemotherapy (N = 51) and chemotherapy alone (N = 54) were retrospectively enrolled in this cohort study. Webb31 juli 2024 · HOUSTON, July 31, 2024 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV) today announced that preliminary efficacy data from their ongoing clinical trial with AVB-500 showed compelling anti-tumor activity in the 12 patients treated from the first cohort of the ongoing Phase 1b portion of the Phase 1b/2 trial of AVB-500 in patients with … parks inn harpur hill buxton

A source of hope for platinum-resistant ovarian cancer?

Current Standards of Care in Platinum-Resistant Ovarian Cancer

Webb15 dec. 2024 · Two phase II trials have tested this concept in people with platinum-resistant and unresponsive ovarian cancer. One, run by Dana-Farber and NCI … WebbOvarian cancer (OC) remains a fatal malignancy because most patients experience recurrent disease, which is resistant to chemotherapy. The outcomes for patients with … parks in new york with live musicWebbIn platinum resistant ovarian cancer, nivolumab demonstrated in a phase II trial encouraging safety and clinical efficacy with a RR of 15% (Hamanishi et al., 2015). From: … parks in new york new york

"WebbPujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al.. (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian … " - Platinum resistant recurrent ovarian cancer

Platinum resistant recurrent ovarian cancer

Treatment of platinum-resistant ovarian cancer - PubMed

Webb26 apr. 2024 · The aim of treatment in recurrent or refractory epithelial ovarian cancer is palliation. In a patient with platinum-resistant status, several chemotherapy regimens have been reported with similar response rates. Among these agents, the oral etoposide holds an advantage of the route of administration and management in the out-patient setting. Webb8 apr. 2024 · Platinum-resistant disease: For a recurrence that develops less than 6 months after the completion of initial therapy, one of the following single-agent regimens may be considered: Pegylated...

Did you know?

WebbOf the 38 women enrolled, 18 had platinum-resistant with an ORR of 16.7% (95% CI 3.6–41.4%) compared to an ORR of 40% in platinum-sensitive cohort. Median PFSPFS by … Webb8 juni 2024 · Physical function and abdominal/gastrointestinal symptom scores improved predictions of overall survival over clinicopathological factors alone in platinum …

WebbResistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer, contributing to the high mortality-to-incidence ratio. Management of the … Webb10 apr. 2024 · Treatment with botensilimab plus balstilimab produced responses in patients with refractory or resistant ovarian cancer, according to results from a phase 1 …

Webb11 apr. 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be determined. Therefore, this Bayesian network meta-analysis was conducted to investigate the optimal treatment options for recurrent platinum-resistant ovarian cancer.MethodsPubmed, … Webbdefinition of platinum resistance In this substudy, platinum resistance was classified further according to response to previous anticancer treatments. PPR was defined as progression <6 months after completing first-line platinum-based chemotherapy (one or two chemotherapy regimens allowed).

WebbOvarian cancer is the leading cause of death for patients with gynecologic malignancies, and the standard first-line treatment is platinum-based chemotherapy and tumor cytoreductive surgery. 1 Although most ovarian cancer patients are sensitive to platinum-based chemotherapy, about 80% patients relapse within 1 to 2 years after initial …

Webb6 maj 2024 · At present, the standard treatment for platinum-resistant ovarian cancer patients is platinum-free chemotherapy, with poor efficacy and tolerance. The combination of anti-angiogenic drugs and PARPi can play a synergistic anti-tumor role and achieve good efficacy in platinum-sensitive recurrent ovarian cancer. timmins aceWebbThis study aimed to further explore the efficacy and safety of apatinib plus chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC). Methods: Totally, … parks in new york upstateWebbStudy 19 and its subsequent analyses found that olaparib maintenance monotherapy significantly improved PFS in women with platinum-sensitive recurrent ovarian cancer … parks in new york with cabinsWebb9 mars 2024 · For patients with platinum-sensitive recurrent ovarian cancer, we usually choose carboplatin (carbo) in combination with paclitaxel (PAC) as the first-line standard chemotherapy regimen, but this regimen exhibits more non-hematologic toxicity, which results in early discontinuation of treatment. timmins aboriginal housingWebbOne solution to improve treatment for platinum-resistant ovarian cancer would be the development of precision medicine. 14–16 Since the odds associated with this type of … timmins academyWebb11 apr. 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be … timmins 50/50 drawWebb23 jan. 2024 · However, platinum-resistant recurrent ovarian cancer remains a clinical challenge with few effective therapeutic options. The DNA and RNA helicase Schlafen family member 11 (SLFN11) has been studied for its potential role in translation of DNA damage response proteins. timmins activities